Molecular Partners Ag Adr stock is traded at $3.22, with a volume of 4,790. It is down -0.98% in the last 24 hours and down -14.95% over the past month. Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Previous Close:
$3.25
Open:
$3.38
24h Volume:
4,790
Relative Volume:
1.96
Market Cap:
$123.25M
Revenue:
$786.00K
Net Income/Loss:
-$72.06M
P/E Ratio:
-
EPS:
-$1.93
Net Cash Flow:
-$59.83M
1W Performance:
-10.20%
1M Performance:
-14.95%
6M Performance:
-24.98%
1Y Performance:
-31.30%
1-Day Range:
$0.00$0.00
1-Week Range:
$3.09$3.60
52-Week Range:
$3.09$5.36
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS